Positron Corporation (POSC)

[roelien]

More DD part 1 from today's PR"

1.'Radiopharmaceuticals, Sestimibi and Rubidium, are now available as a generic pharmaceutical and are set to become commercially available with a number of pharma companies. Lower cost and increased suppliers will help grow our segment of the industry. Positron is working with the largest companies in this field.

- Rubidium (brand name CardioGen 82R). The only generator-based Positron Emission Tomography agent reimbursed for the evaluation of coronary artery disease. Only supplied by Bracco Diagnostics to the industry. On September 23 2008, Bracco Diagnostics Inc., the US-based subsidiary of Bracco Imaging SpA and part of the Bracco Group, and Lantheus Medical Imaging, Inc., both worldwide leaders in diagnostic imaging, announced today that the companies have entered into an agreement for Lantheus to co-promote Bracco’s CardioGen-82® (Rubidium Rb 82 Generator), a myocardial perfusion Positron Emission Tomography (PET) imaging agent. CardioGen-82 is the only generator-based PET perfusion agent approved by the U.S. Food and Drug Administration (FDA) and reimbursed for the evaluation of coronary artery disease (CAD).

- Sestimibi (brand name Cardio Lite). Cardio Lite is manufactured by Lantheus. Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien’s generic product is fully substitutable for Cardiolite(R), a myocardial perfusion imaging agent used for detecting coronary artery disease. Covidien got approval for the generic kit in July 2008 and has approval for sale and distribution in the the U.K., Denmark, Germany and Puerto Rico. A ANDS in Canada is pending. Pharmalucence also got approval for the generic version in Jyly 2009.